DOI: 10.1177/09612033261465933 ISSN: 0961-2033

Association of serum and urinary galectin-3 with renal fibrosis in patients with lupus nephritis: A cross-sectional controlled study

Ahmed Mohamed Fahmy, Rasha Youssef Hagag, Amira Mahmoud Radwan, Asmaa Mounir Emara, Ahmed Abdelazim Elmoghany
Show PDF Cite

Objective

Our objective was to explore the correlation between serum (sGal-3) and urinary galectin-3 (uGal-3) levels and renal fibrosis (RF) severity in lupus nephritis (LN) patients, besides assessing their diagnostic performance for identifying moderate/severe interstitial fibrosis and tubular atrophy (IFTA).

Methods

This cross-sectional controlled study recruited 150 participants: 50 LN patients, 50 diagnosed with systemic lupus erythematosus (SLE) without LN, and 50 healthy controls. Both sGal-3 and uGal-3 levels were measured using ELISA. Histopathological assessment included evaluation of IFTA severity. Patients with LN were stratified into mild IFTA (<26%) and moderate/severe IFTA (≥26%). Moreover, we performed correlation, ROC curve, and multivariable logistic regression analyses.

Results

LN patients showed significantly higher sGal-3 and uGal-3 levels than other groups ( p < 0.001). Both biomarkers exhibited strong positive correlations with IFTA percentage (sGal-3: rho = 0.76; uGal-3: rho = 0.81; p < 0.001). Unlike those with mild IFTA, moderate/severe IFTA patients had significantly higher sGal-3 and uGal-3 levels ( p < 0.001). Based on ROC analysis, uGal-3 had higher discriminatory ability for moderate/severe IFTA (AUC = 0.903) than sGal-3 (AUC = 0.801). In multivariable logistic regression, both sGal-3 and uGal-3 levels were independently associated with moderate/severe IFTA after adjusting for renal function parameters.

Conclusions

Both sGal-3 and uGal-3 levels are significantly associated with RF severity in LN. The uGal-3 had superior diagnostic performance for moderate/severe IFTA and may be a promising non-invasive RF biomarker in LN. Validation in large-scale prospective studies is warranted.

More from our Archive